future of glp 1 drugs GLP-1 Market Size to Hit USD 132.79 Bn by 2035 GLP-1 Pipeline Update: February 2025

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

Promotes a healthy blood sugar response*: Reducose slows down the breakdown of carbs to reduce post-meal glucose spikes by up to 40%, while Feiolix supports insulin sensitivity and glucose metabolism.

Plant-Based Insulin Modulation Ceylon Cinnamon and Berberine help maintain a balanced response to glucose intake, supporting steady energy levels throughout the day.

More and more evidence is showing that the use of DPP4 Inhibitors and GLP1 Receptor Agonists in combination, is a practice worth changing

The diabetes indication segment accounted for the largest share of the market

Quality Assurance & Verification